Albany, NY -- (SBWIRE) -- 12/13/2016 -- North America leads the global erectile dysfunction market and according to recent studies the region will continue to remain the largest market for erectile dysfunction drugs such as Cialis and Viagra over the next few years. While factors such as an increase in geriatric population and growing preference towards a sedentary lifestyle is expected to create an increased demand for erectile dysfunction drugs, the market on the whole might suffer a backlash owing to the rising incidence of sexually transmitted diseases and growing threat of counterfeit drugs. According to a recent research conducted to study the incumbent trends, the global erectile dysfunction drugs market, worth US$4.3 billion in 2012, is anticipated to reach US$3.4 billion by the end of 2019, registering decline at a CAGR of -4.5% between 2013 and 2019.

Download Exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1550

Erectile dysfunction is a condition in men that defines their inability to attain penile erection. It is a common medical disorder that primarily affects men above the age of 40 years. Men suffering from diabetes and hypertension might also face the problem of erectile dysfunction. Apart from this, there are many lifestyle-related factors such as smoking, obesity, excessive consumption of alcohol, drug addiction, and poor physical and psychological health that can trigger the condition of erectile dysfunction among men.

Patent Expiration of Major Pharmaceutical Giants to Hinder Growth in Global Erectile Dysfunction Drugs Market

The global market for erectile dysfunction drugs is on the verge of suffering a huge setback. Industry experts are of the view that the global demand for erectile dysfunction drugs will decline drastically before 2019 ends. The market suffered its first jolt with the end patent exclusivity granted to Viagra in the U.S. in 2013. Moreover, patent exclusivities for Levitra by Bayer AG and Cialis by Eli Lilly & Co are also slated to end by 2019, which would further cut down the revenue of the global erectile dysfunction drugs market. Generic manufacturers will benefit the most from the resultant vacuum. They will have a chance to claim the major share of the global market by launching personalized versions of these brands. Apart from this, the low rate of success registered by novel drug formulations also account for the slump that the global erectile dysfunction drugs market is projected to witness.

Viagra Will Maintain Major Revenue Share Due to Extended Exclusivity

Viagra accounted for 45% of the total revenue earned by the global erectile dysfunction drugs market in 2012. However, the overall market revenue for erectile dysfunction drug is anticipated to decline rapidly owing to the loss of the drug's patent exclusivity in Europe and many other major markets. However, the extended lease of life granted to Viagra will help it maintain strong revenue until 2020, whereas the global market for the second-largest contributor, Cialis, is projected to decline at a CAGR of 12.6% from a value of US$1,926.8 million in 2012, since its patent exclusivity will expire sooner, in 2017. In addition to this, the patent exclusivity for Bayer's Levitra is also slated to expire in 2018, which will bring down the revenue for the global erectile dysfunction drug market even further.

North America to Continue to Dominate Global Erectile Dysfunction Drug Market

On the basis of revenue, North America dominated the global erectile dysfunction drugs market in 2012 and is anticipated to continue its run as the market leader in the forthcoming years. The extended patent exclusivity granted to Viagra in the U.S. till 2020 will help the region maintain its position as the market leader over the next couple of years. The increase in demand for erectile dysfunction drugs had helped Europe emerge as the second largest regional market in 2012.

The global market for erectile dysfunction drugs is primarily dominated by companies such as Eli Lilly & Co, Pfizer Inc., Bayer AG, Vivus Inc., and Dong-A Pharmaceutical Co Ltd

About Transparency Market Research
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company's exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact Us
Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com